baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Amarin Corp/ US0231112063 /

2024-04-15 9:59:35 PM	Chg. -0.04	Volume	Bid-	Ask-	High	Low
0.92USD	-4.35%	7,033 Turnover: 6,527.08	-Bid Size: -	-Ask Size: -	0.96	0.92

GlobeNewswire 04-15 Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

GlobeNewswire 04-08 Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

GlobeNewswire 04-06 New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular...

GlobeNewswire 04-03 Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

GlobeNewswire 03-25 Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American ...

GlobeNewswire 03-22 Theratechnologies Appoints Jordan Zwick to its Board of Directors

GlobeNewswire 02-29 Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 02-15 Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February...

GlobeNewswire 01-22 Amarin Chairman & CEO Issue Letter to Shareholders

GlobeNewswire 01-10 Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For ...

GlobeNewswire 2023-12-11 Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-04 Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Oth...

GlobeNewswire 2023-11-12 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Red...

GlobeNewswire 2023-11-01 Amarin Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-31 Lexicon Strengthens Management Team With Two New Executives

GlobeNewswire 2023-10-31 Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

GlobeNewswire 2023-10-26 Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Land...

GlobeNewswire 2023-10-19 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

GlobeNewswire 2023-09-12 Amarin to Present at the 2023 Cantor Global Healthcare Conference

GlobeNewswire 2022-03-28 Amarin Receives Reimbursement for VAZKEPA® in Sweden

GlobeNewswire 2022-03-22 CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire 2022-03-21 Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Car...

GlobeNewswire 2022-03-10 Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal...

GlobeNewswire 2022-02-25 Amarin to Participate in Cowen 42nd Annual Health Care Conference

GlobeNewswire 2022-02-24 JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cos...

Amarin Corp/ US0231112063 /

If you wish to receive reply to your feedback, please provide your email address.